Innovative access agreements for ATMPs in Europe

Why embrace them?

By Chloe Sheppard, Erfan Akbraian, Andrea Bernardini & Richard Wang

Advanced Therapy Medicinal Products (ATMPs) have significant potential to transform the lives of patients by delivering remarkable, durable improvements in clinical outcomes, in addition to providing long-term cost-savings to healthcare budgets.
Manufacturers often face challenges with securing reimbursement and access for high-cost ATMPs, primarily due to clinical data uncertainties and budget impact concerns of healthcare payers, as well as the fact that current reimbursement and funding systems are not yet adapted to pay for one-time therapies.

Please enter your details in the form on the right to download the full text

Register to download whitepaper

Please enter your details if you want to download the full whitepaper.

    Share post